Clinical Trial Update: Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol [Phase 3]

View source ↗

Summary

Phase 3 trial update for inclisiran in subjects with atherosclerotic cardiovascular disease or risk-equivalents and elevated LDL cholesterol.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Cardiovascular Risk Factors
• Hyperlipidemia

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: The Medicines Company | Conditions: ASCVD, Risk Factor, Cardiovascular | Phase 3 | Status: COMPLETED | Results posted: 2020-08-21